<DOC>
	<DOCNO>NCT02457104</DOCNO>
	<brief_summary>The investigator long-term goal understand PPIs influence energy balance obese normal-weight individual . The overall goal study determine whether PPI use cause detrimental change composition functional property gut microbiome , whether effect mediate altered response human fatty acid receptor ( e.g. , GPR41/43 ) .</brief_summary>
	<brief_title>The Effect PPI Therapy Weight , Gut Microbiome , Expression GPR41 GPR43</brief_title>
	<detailed_description>Research Plan : Patients without gastrointestinal symptom schedule screen surveillance colonoscopy ( colorectal cancer ) UCH endoscopy lab screen study base inclusion exclusion criterion . Eligible patient consent study height , weight , demographic information measure record . They complete weight/diet history questionnaire . Patients undergo screening/surveillance colonoscopy per routine clinical care . Residual stool standardly aspirate colonoscope ensure full visualization mucosa enhance polyp detection . We take stool aspirate three separate location : sigmoid colon , cecum , terminal ileum . Evidence suggest bowel preparation ( prior colonoscopy ) significantly change composition intestinal microbiota majority subject . We also take four small , pinch biopsy three site . Stool aspirate biopsy specimen snap-frozen liquid N2 frozen -80C require assay . We enroll total 48 subject divide equally four group : OB/PPI , OB/non-PPI , NW/PPI , NW/non-PPI . Approximately 40-50 patient per week meeting inclusion/exclusion criterion undergo screening/surveillance colonoscopy UCH , make recruitment 2-3 patients/week 6-9 month realistic reach target enrollment . Aim 1 : To examine effect PPI use gut microbiota colon terminal ileum normal-weight ( NW ) obese ( OB ) patient . Intestinal microbiomes profile 16S rRNA sequence identify PPI-associated alteration gut biodiversity . Separate sterile specimen collection container use stool aspirate mucosal biopsy sigmoid colon , cecum , terminal ileum . High-throughput DNA sequence microbiome analysis use . Microbiome 16S rRNA Profiling Total community genomic DNA prepare intestinal specimen 16S rRNA gene PCR amplify previously describe . Paired-end , multiplexed sequencing perform . 10-20 million DNA sequence generate single run 100,000 rRNA read generate per sample ensure &gt; 99 % sequence coverage . Demultiplexing , quality filtering , chimera-removal sequence classification ( use SINA/Silva ) follow previous publication . Similar sequence group operational taxonomic unit ( OTUs ) base taxonomy . Microbiome Data Analysis The main outcome percent relative abundance ( PRA ) microbial group , hypothesize differ PPI user non-users acid suppression medication . Specific microbial group ( species/genera/phyla ) differ experimental group identify use non-parametric two-part statistic.40 Statistical analysis assess = 0.05 p-values correct false discovery rate ( FDR ) .41 Results validate species-specific QPCR . Aim 2 : To determine whether PPI use alters relative amount gut bacterial RNA dedicate fermentation cycle NW OB individual . We perform shotgun sequence bulk RNA prepare intestinal microbiomes identify microbial metabolic pathway differentially express patient PPIs . Stool aspirate terminal ileum , cecum , sigmoid colon obtain detail . RNA Isolation Sequencing Microbial RNA extract 50 mg fecal aspirate use RiboPure Bacteria extraction kit ( Life Technologies Inc. , USA ) . For pilot , assay specimen total 48 subject divide equally four group : OB/PPI , OB/non-PPI , NW/PPI , NW/non-PPI . Host microbial rRNA remove use Ribo-Zero bacteria Ribo-Zero mouse kit ( Epicentre , Inc , USA ) . RNA sample prepare sequence use ScriptSeq v2 RNA-Seq ( bacteria ) kit ( Epicentre , Inc , USA ) . Sequencing perform Illumina HiSeq2000 platform ( UC-Denver Microarray Genomics Core ) , provide high depth coverage . For quality assurance reproducibility , two mRNA sample specimen pool sequence . In pilot experiment , generate ~20x106 single-end 150-base read per sample microbial meta-transcriptome dataset . Metatranscriptome Data Analysis Annotation enumeration bacterial transcript perform peptide level use BLASTX search approximately 1800 bacterial genome sequence currently available GenBank well NCBI non-redundant protein database use E-value cutoff &lt; 10-5.44 Broad-level functional difference sample assess use annotation generate COG,47 KEGG48 RAST/SEED tools.49 , 50 Statistical analysis enteric microbial transcriptomes focus identification metabolic pathways differentially express groups.44 Genes high-quality annotation ( E &lt; 10-5 ) use construct NxM matrix gene ( M ) subject ( N ) record number sequence read annotate give gene subject . A similar NxM matrix gene category ( M ) subject ( N ) construct tabulate distribution sequence read assign functional category . Genes gene category differ prevalence abundance treatment group identify Fisher exact test Kruskal-Wallis test , respectively , apply gene/category matrix . Significance assess = 0.05 , follow correction FDR.41 P-values use prioritize candidate gene list follow-up validation use QPCR screen gene expression across entire patient cohort . Aim 3 : To determine extent PPI use alters expression GPR41 , GPR43 , effector gene colon terminal ileum NW OB patient . Biopsy specimens subject panel RT-QPCR assay monitor expression target gene impact microbial SCFA production . Biopsies terminal ileum , cecum , sigmoid colon obtain detailed . Quantitative reverse transcriptase-PCR ( qRT-PCR ) analysis Total RNA extract use RNeasy Mini Kit ( Qiagen ) ISOGEN ( WAKO ) . Complementary DNAs transcribe use RNAs templates Moloney murine leukaemia virus reverse transcriptase ( Invitrogen ) . cDNAs amplify PCR Taq DNA polymerase ( TaKaRa ) use appropriate primer . qRT-PCR analysis perform use DNA Engine Opticon-2 ( MJ Research ) . The expression quantify duplicate . Sample Size Power Analysis : We enroll 24 NW 24 obese ( OB ) participant . Half NW OB group PPI user half non-users acid suppress medication . The primary outcome Aim 1 difference PRA Firmicutes Bacteroidetes . A two-way ANOVA ( factor BMI category PPI use ) use . Based preliminary data , 94 % power detect difference PRA Firmicutes ( 72 % vs 52 % SD 20 % ) 95 % power detect difference PRA Bacteroidetes ( 16 % vs 5 % SD 5 % ) PPI user non-users . The primary outcome Aim 2 difference bacterial RNA dedicate fermentation cycle outcome Aim 3 difference expression GPR 41 GPR 43 . Based expected difference gut microbiota profile subsequent SCFA production , expect 25 % difference PPI user non-users outcome , give u 99 % power Aims 2 3 ) . We also perform subgroup analysis within NW OB group .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<criteria>1. asymptomatic ( complaint abdominal pain , diarrhea , blood stool , constipation , etc . ) 2. age 4059 year 3 . PPI user ( Use PPI â‰¥ 4 days/week precede 8 week ) nonusers acid suppress medication ( use PPI H2B previous 8 week ) 4 . BMI either normalweight ( BMI 18.5 &lt; 25 kg/m2 ) Class I/ II obese ( BMI 30 &lt; 40 kg/m2 ) . 1. probiotic antibiotic use within 3 month colonoscopy 2. inflammatory bowel disease 3. personal history colon cancer 4. resection portion gastrointestinal tract ( include appendectomy cholecystectomy ) 5. diabetes 6 . Significant motility disorder GI tract ( e.g. , gastroparesis , colonic inertia ) 7 . Use immunosuppressive medication within past 6 month 8. pregnancy/lactation 9 . HIV immune deficiency 10. prisoner</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>